Terms: = Lung cancer AND RPL22, EAP, 6146
50 results:
1. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Passiglia F; Lucia Reale M; Lo Russo G; Pasello G; Minuti G; Bulotta A; Galetta D; Pelizzari G; Sini C; Bria E; Roca E; Pilotto S; Genova C; Metro G; Citarella F; Chiari R; Cortinovis D; Delmonte A; Russo A; Tiseo M; Cerea G; Carta A; Scotti V; Vavalà T; Brambilla M; Buffoni L; Buosi R; Catania C; Gori S; Grisanti S; Agustoni F; Garbo E; Malapelle U; Novello S
Lung Cancer; 2024 Jan; 187():107444. PubMed ID: 38157806
[TBL] [Abstract] [Full Text] [Related]
2. Expanded Access Program Pralsetinib in Advanced Non-Small Cell lung cancer with Rearranged during Transfection (RET) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract] [Full Text] [Related]
3. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (eap).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract] [Full Text] [Related]
4. Bioinformatics Identification of Key Genes for the Development and Prognosis of lung Adenocarcinoma.
Luo X; Xu JG; Wang Z; Wang X; Zhu Q; Zhao J; Bian L
Inquiry; 2022; 59():469580221096259. PubMed ID: 35635202
[TBL] [Abstract] [Full Text] [Related]
5. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract] [Full Text] [Related]
6. Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme.
Chan OSH; Lee VHF; Nyaw SF; Kam MTY; Lee KWC; Lam KC
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e305-e314. PubMed ID: 33589348
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of the Kinetic Mechanism of Human Protein Arginine Methyltransferase 5.
Eddershaw AR; Stubbs CJ; Edwardes LV; Underwood E; Hamm GR; Davey PRJ; Clarkson PN; Syson K
Biochemistry; 2020 Dec; 59(50):4775-4786. PubMed ID: 33274632
[TBL] [Abstract] [Full Text] [Related]
8. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (eap).
Faehling M; Schumann C; Christopoulos P; Hoffknecht P; Alt J; Horn M; Eisenmann S; Schlenska-Lange A; Schütt P; Steger F; Brückl WM; Christoph DC
Lung Cancer; 2020 Dec; 150():114-122. PubMed ID: 33126091
[TBL] [Abstract] [Full Text] [Related]
9. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract] [Full Text] [Related]
10. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
[TBL] [Abstract] [Full Text] [Related]
11. Real-world data from the Portuguese Nivolumab Expanded Access Program (eap) in previously treated Non Small Cell lung cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract] [Full Text] [Related]
12. Italian Cohort of the Nivolumab eap in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.
Cortinovis D; Chiari R; Catino A; Grossi F; DE Marinis F; Sperandi F; Piantedosi F; Vitali M; Parra HJS; Migliorino MR; Tondini C; Tassinari D; Frassoldati A; Verderame F; Pazzola A; Cognetti F; Palmiotti G; Marchetti P; Santoro A; Giannarelli D; Colonese F; Delmonte A
Anticancer Res; 2019 Aug; 39(8):4265-4271. PubMed ID: 31366516
[TBL] [Abstract] [Full Text] [Related]
13. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
Stratmann JA; Michels S; Hornetz S; Christoph DC; Sackmann S; Spengler W; Bischoff H; Schäfer M; Alt J; Müller A; Laack E; Kimmich M; Griesinger F; Sebastian M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2457-2463. PubMed ID: 30244389
[TBL] [Abstract] [Full Text] [Related]
15. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
[TBL] [Abstract] [Full Text] [Related]
16. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O; Vogelzang NJ; Sweeney C; Fernandez DC; Almeida F; Iagaru A; Brown A; Smith MR; Agrawal M; Dicker AP; Garcia JA; Lutzky J; Wong YN; Petrenciuc O; Gratt J; Shore ND; Morris MJ;
Oncologist; 2018 Feb; 23(2):193-202. PubMed ID: 29183960
[TBL] [Abstract] [Full Text] [Related]
17. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Tumeh PC; Hellmann MD; Hamid O; Tsai KK; Loo KL; Gubens MA; Rosenblum M; Harview CL; Taube JM; Handley N; Khurana N; Nosrati A; Krummel MF; Tucker A; Sosa EV; Sanchez PJ; Banayan N; Osorio JC; Nguyen-Kim DL; Chang J; Shintaku IP; Boasberg PD; Taylor EJ; Munster PN; Algazi AP; Chmielowski B; Dummer R; Grogan TR; Elashoff D; Hwang J; Goldinger SM; Garon EB; Pierce RH; Daud A
Cancer Immunol Res; 2017 May; 5(5):417-424. PubMed ID: 28411193
[TBL] [Abstract] [Full Text] [Related]
18. Mutation Profiling of lung cancers with Long-Term Response to Gefitinib Therapy.
Gautschi O; Stadelmann C; Aebersold-Keller F; König K; Büttner R; Heukamp LC; Betticher D; Baumann C; Buser K; Calderoni A; Casty A; DʼAddario G; Irlé C; Mamot C; Morant R; Trojan A; Pellicioli E; Jehle-Schwertfeger S; Aebi S; Diebold J
Oncol Res Treat; 2015; 38(11):560-9. PubMed ID: 26599269
[TBL] [Abstract] [Full Text] [Related]
19. Interaction of ribosomal protein L22 with casein kinase 2α: a novel mechanism for understanding the biology of non-small cell lung cancer.
Yang M; Sun H; He J; Wang H; Yu X; Ma L; Zhu C
Oncol Rep; 2014 Jul; 32(1):139-44. PubMed ID: 24840952
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression, purification, molecular characterization and the effect on tumor growth of ribosomal protein L22 from the Giant Panda (Ailuropoda melanoleuca).
Li J; Hou Y; Ding X; Hou W; Song B; Zeng Y
Mol Biol Rep; 2014 May; 41(5):3529-39. PubMed ID: 24504451
[TBL] [Abstract] [Full Text] [Related]
[Next]
